Your browser doesn't support javascript.
loading
Phase 1 dose-escalation study of mirvetuximab soravtansine (IMGN853), a folate receptor α-targeting antibody-drug conjugate, in patients with solid tumors.
Moore, Kathleen N; Borghaei, Hossein; O'Malley, David M; Jeong, Woondong; Seward, Shelly M; Bauer, Todd M; Perez, Raymond P; Matulonis, Ursula A; Running, Kelli L; Zhang, Xiaoyan; Ponte, Jose F; Ruiz-Soto, Rodrigo; Birrer, Michael J.
Afiliação
  • Moore KN; Department of Obstetrics and Gynecology, University of Oklahoma Health Sciences Center, Oklahoma City, Oklahoma.
  • Borghaei H; Department of Hematology/Oncology, Fox Chase Cancer Center, Philadelphia, Pennsylvania.
  • O'Malley DM; Department of Obstetrics and Gynecology, The Ohio State University College of Medicine, Columbus, Ohio.
  • Jeong W; Cancer Therapy and Research Center, University of Texas Health Science Center, San Antonio, Texas.
  • Seward SM; Department of Obstetrics and Gynecology, Wayne State University, Detroit, Michigan.
  • Bauer TM; Sarah Cannon Research Institute/Tennessee Oncology, PLLC, Nashville, Tennessee.
  • Perez RP; Division of Hematology/Oncology, University of Kansas, Fairway, Kansas.
  • Matulonis UA; Department of Medical Oncology, Dana Farber Cancer Institute, Boston, Massachusetts.
  • Running KL; ImmunoGen, Inc., Waltham, Massachusetts.
  • Zhang X; ImmunoGen, Inc., Waltham, Massachusetts.
  • Ponte JF; ImmunoGen, Inc., Waltham, Massachusetts.
  • Ruiz-Soto R; ImmunoGen, Inc., Waltham, Massachusetts.
  • Birrer MJ; Gillette Center for Gynecologic Oncology, Massachusetts General Hospital, Boston, Massachusetts.
Cancer ; 123(16): 3080-3087, 2017 Aug 15.
Article em En | MEDLINE | ID: mdl-28440955

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Imunoconjugados / Anticorpos Monoclonais Humanizados / Maitansina / Neoplasias / Antineoplásicos Limite: Aged80 Idioma: En Revista: Cancer Ano de publicação: 2017 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Imunoconjugados / Anticorpos Monoclonais Humanizados / Maitansina / Neoplasias / Antineoplásicos Limite: Aged80 Idioma: En Revista: Cancer Ano de publicação: 2017 Tipo de documento: Article